Citadel Advisors’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,400
| Closed | -$21K | – | 12408 |
|
|
2025
Q1 | $21K | Sell |
1,400
-500
| -26% | -$8.32K | ﹤0.01% | 13105 |
|
|
2024
Q4 | $31.3K | Buy |
1,900
+1,800
| +1,800% | +$35.5K | ﹤0.01% | 12838 |
|
|
2024
Q3 | $2.47K | Sell |
100
-4,900
| -98% | -$127K | ﹤0.01% | 13747 |
|
|
2024
Q2 | $127K | Sell |
5,000
-1,300
| -21% | -$33.7K | ﹤0.01% | 10580 |
|
|
2024
Q1 | $160K | Buy |
6,300
+4,800
| +320% | +$116K | ﹤0.01% | 10664 |
|
|
2023
Q4 | $34K | Buy |
1,500
+700
| +88% | +$14.5K | ﹤0.01% | 12157 |
|
|
2023
Q3 | $14.9K | Buy |
800
+700
| +700% | +$14.5K | ﹤0.01% | 12849 |
|
|
2023
Q2 | $2.6K | Sell |
100
-900
| -90% | -$24.1K | ﹤0.01% | 13764 |
|
|
2023
Q1 | $28.7K | Buy |
+1,000
| New | +$29.8K | ﹤0.01% | 12774 |
|
|
2021
Q2 | – | Sell |
-5,200
| Closed | -$212K | – | 13605 |
|
|
2021
Q1 | $212K | Buy |
+5,200
| New | +$197K | ﹤0.01% | 11575 |
|
|
2020
Q2 | – | Sell |
-9,600
| Closed | -$278K | – | 9718 |
|
|
2020
Q1 | $278K | Sell |
9,600
-5,700
| -37% | -$231K | ﹤0.01% | 7472 |
|
|
2019
Q4 | $793K | Sell |
15,300
-136,000
| -90% | -$7.9M | ﹤0.01% | 6009 |
|
|
2019
Q3 | $8.3M | Buy |
+151,300
| New | +$7.77M | ﹤0.01% | 2446 |
|
|
2018
Q4 | – | Sell |
-6,700
| Closed | -$283K | – | 9042 |
|
|
2018
Q3 | $283K | Buy |
6,700
+400
| +6% | +$15.8K | ﹤0.01% | 7661 |
|
|
2018
Q2 | $202K | Buy |
+6,300
| New | +$259K | ﹤0.01% | 7875 |
|
|
2016
Q3 | – | Sell |
-7,700
| Closed | -$413K | – | 7197 |
|
|
2016
Q2 | $413K | Buy |
+7,700
| New | +$363K | ﹤0.01% | 4751 |
|
|
2016
Q1 | – | Sell |
-4,300
| Closed | -$164K | – | 6690 |
|
|
2015
Q4 | $164K | Buy |
4,300
+1,100
| +34% | +$42.1K | ﹤0.01% | 6067 |
|
|
2015
Q3 | $102K | Buy |
3,200
+1,800
| +129% | +$62.8K | ﹤0.01% | 6936 |
|
|
2015
Q2 | $46K | Sell |
1,400
-1,400
| -50% | -$49.9K | ﹤0.01% | 7697 |
|
|
2015
Q1 | $115K | Buy |
2,800
+1,400
| +100% | +$56.6K | ﹤0.01% | 6730 |
|
|
2014
Q4 | $57K | Sell |
1,400
-2,900
| -67% | -$113K | ﹤0.01% | 7094 |
|
|
2014
Q3 | $158K | Sell |
4,300
-4,300
| -50% | -$186K | ﹤0.01% | 5975 |
|
|
2014
Q2 | $398K | Sell |
8,600
-16,600
| -66% | -$738K | ﹤0.01% | 4696 |
|
|
2014
Q1 | $1.04M | Buy |
25,200
+13,200
| +110% | +$491K | ﹤0.01% | 3373 |
|
|
2013
Q4 | $458K | Buy |
12,000
+10,900
| +991% | +$336K | ﹤0.01% | 4132 |
|
|
2013
Q3 | $26K | Buy |
+1,100
| New | +$24.7K | ﹤0.01% | 6088 |
|
Other funds holding ANIK
CP
VCM
BFM
CM
Citadel Advisors's ANIK Position: Q1 2026 in Review
Citadel Advisors increased its Anika Therapeutics (ANIK) stake by 11% in Q1 2026, buying an estimated $58K and bringing the position to 52,062 shares worth $755K. The position accounts for ﹤0.01% of the portfolio, ranked #8340.
Citadel Advisors first reported a position in ANIK in Q2 2013 and has held it in 47 quarters since. The position peaked at $7.05M in Q3 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.
- Citadel Advisors held 52,062 shares of Anika Therapeutics worth $755K as of Q1 2026.
- Citadel Advisors bought 4,996 Anika Therapeutics shares in Q1 2026, an estimated $58K.
- Anika Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8340 holding.
- Citadel Advisors first reported a position in Anika Therapeutics in Q2 2013 and has held it in 47 quarters since.
- Citadel Advisors's Anika Therapeutics position peaked at $7.05M in Q3 2019.
- 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.